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Abstract
Aneuploidy, an imbalanced chromosome number, is associated with both cancer and 
developmental disorders such as Down syndrome (DS). To determine how aneuploidy affects 
cellular and organismal physiology, we have developed a system to evaluate aneuploid cell fitness 
in vivo. By transplanting hematopoietic stem cells (HSCs) into recipient mice after ablation of 
recipient hematopoiesis by lethal irradiation, we can directly compare the fitness of HSCs derived 
from a range of aneuploid mouse models with that of euploid HSCs. This experimental system can 
also be adapted to assess the interplay between aneuploidy and tumorigenesis. We hope that 
further characterization of aneuploid cells in vivo will provide insight both into the origins of 
hematopoietic phenotypes observed in DS individuals as well as the role of different types of 
aneuploid cells in the genesis of cancers of the blood.
Aneuploidy is a state in which cells harbor a chromosome number that is not a whole 
number multiple of the haploid chromosome complement. It is the cause of developmental 
disorders such as Down syndrome (DS; trisomy 21). Aneuploidy is also a feature of cancer 
cells and has been hypothesized to drive cancer cell proliferation (Boveri 1914). In recent 
years, research evaluating the effects of aneuploidy on cell physiology and investigating its 
role in cancer have greatly increased our understanding of this complicated cellular state. A 
number of model systems have been developed to study cells with increased rates of 
chromosome mis-segregation— chromosomal instability (CIN)—and the result of such 
chromosome mis-segregation events—aneuploidy—in tumorigenesis. However, the precise 
role of aneuploidy in cancer still remains unclear, as it has been shown to both promote and 
inhibit tumorigenesis in different model systems (Pfau and Amon 2012).
By studying aneuploidy per se, we have learned that whole chromosome gains and losses 
have a profound effect on cells and organisms (Santaguida and Amon 2015). Such large 
genomic alterations affect a multitude of cellular processes, from transcription and 
translation, to protein folding and degradation. Cells respond with a characteristic stress 
response, proliferating slowly and up-regulating protein quality control pathways. Because 
of its severe impact on cell physiology and development, aneuploidy is often lethal in 
multicellular organisms, and the few aneuploidies that do not cause lethality lead to reduced 
growth and developmental abnormalities.
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To date, much of the work characterizing aneuploid cells has been performed in cell culture 
or in animal models of DS or CIN. While these systems have revealed some features of the 
aneuploid cell condition, they did not provide a complete picture of the effects of aneuploidy 
on cell physiology in vivo. Cell culture systems are limiting in that cells are studied outside 
the natural context of the organism. Mouse models of DS only permit study of the 
amplification of genes present on human chromosome 21. Mouse models of CIN do not 
solely examine the effects of aneuploidy but also evaluate events associated with 
chromosome mis-segregation such as DNA damage (Janssen et al. 2011; Crasta et al. 2012). 
Because of these limitations, it is important to develop additional model systems for the 
study of aneuploidy to better understand how aneuploidy affects cell physiology and to 
dissect the relationship between aneuploidy and cancer. Towards this goal, we have 
established an experimental system to study aneuploid cells in vivo. By utilizing 
transplantation, the fitness of a range of aneuploid hematopoietic stem cells (HSCs) can be 
evaluated in the context of an otherwise euploid organism. Further, this system has great 
potential to directly assess how aneuploidy affects the kinetics of tumorigenesis in leukemia 
and lymphoma.
HEMATOPOIETIC RECONSTITUTIONS TO STUDY ANEUPLOIDY IN VIVO
Study of the effects of aneuploidy on cellular fitness in vivo is difficult because most 
autosomal aneuploidies are embryonic lethal in mammals (Gropp 1982; Torres et al. 2008). 
We can circumvent this complication in mice by performing transplantation experiments 
with HSCs derived from aneuploid embryos, a procedure called an adoptive transfer. This 
model system is convenient for studying aneuploidy in vivo because HSCs can be isolated 
from embryos and transplanted into euploid adult recipient mice that have undergone lethal 
irradiation, which eliminates recipient hematopoiesis. The blood from recipients of 
aneuploid HSCs can then be evaluated over time to determine the potential of trisomic cells 
in this in vivo context.
Blood contains many cell types, yet all blood cells are derived from a common precursor, the 
HSC. Hematopoiesis, the process by which blood is made, is a hierarchical differentiation 
pathway whereby HSCs divide asymmetrically to generate progenitor cells, which 
subsequently divide to amplify and also differentiate to give rise to all downstream cell types 
(Figure 1). HSCs are found in the bone marrow in adult mice and humans, where they are 
mostly quiescent (Sun et al. 2015; Busch et al. 2015); however, HSCs undergo several 
migrations during embryonic development to reach the bone marrow (Figure 2).
Primitive hematopoiesis is the process of forming blood cells that help sustain the embryo 
during development but do not ultimately contribute to the adult blood after birth. Primitive 
hematopoiesis begins around embryonic day 7.5 (E7.5) with the emergence of yolk sac 
blood islands, which primarily produce primitive erythroid cells (Baron et al. 2012; Mikkola 
and Orkin 2006). This production of red blood cells allows for proper oxygenization of 
embryonic tissues (Orkin and Zon 2008). Definitive hematopoiesis is the process of forming 
blood cells that both sustain the developing embryo and contribute to adult hematopoiesis 
after embryonic development. While there is evidence that HSCs in the yolk sac can also 
contribute to definitive hematopoiesis (Moore and Metcalf 1970; Palis et al. 1999; 
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Samokhvalov et al. 2007), the majority of definitive HSCs are thought to arise from the 
aorta-gonad-mesonephros (AGM) region around E10.5 (Müller et al. 1994). These cells then 
migrate to the developing fetal liver around E11.5, where they rapidly expand for several 
days (Morrison et al. 1995) before gradually entering circulation around E15.5 (Christensen 
et al. 2004). HSCs then “home” to the bone marrow beginning around E17.5 (Christensen et 
al. 2004), where they are recruited to colonize the adult hematopoietic niche by interactions 
with niche cells (Lapidot 2005).
Much of what has been learned about HSCs has been gleaned from transplantation 
experiments. Following whole body irradiation, HSCs apoptose (Meng et al. 2003) or 
senesce (Wang et al. 2006), eliminating HSC function. Most mice die within 14 days after 
exposure to a lethal dose of irradiation due to bone marrow failure (Storer 1966). However, 
when non-irradiated donor HSCs are supplied by injection of fetal liver or bone marrow cell 
suspensions into the bloodstream, these HSCs home to the bone marrow and rapidly 
proliferate to reconstitute the blood and promote long-term survival of the irradiated 
recipient mouse (Figure 3). This “transplantability” of HSCs can be exploited 
experimentally, allowing the evaluation of HSCs of interest in promoting recipient survival 
and contributing to long-term recipient hematopoiesis after irradiation.
Donor- and recipient- derived blood cells can be distinguished by isoform-specific 
antibodies against the pan-leukocyte cell surface marker CD45 (Figure 3), which is present 
in two isoforms in laboratory mice (Morse et al. 1987). Further, using antibodies against cell 
surface markers on blood cells, an immunophenotypic identification scheme has been 
delineated for identifying HSCs and their differentiated progeny, enabling effective 
evaluation of donor HSC contribution to recipient peripheral blood. Thus, this system has 
not only been useful for identifying HSCs, but also for evaluating the fitness of HSCs 
derived from different genetic models, as in (Park et al. 2003).
Taken together, HSCs provide a tractable cellular system to study the effects of aneuploidy 
in vivo for several reasons. First, HSCs can be isolated from both embryos and adults from 
the fetal liver and the bone marrow, respectively, allowing for a range of aneuploid models to 
be tested. Second, the fitness of different aneuploid HSCs can be evaluated by comparing 
recipient survival and performing immunophenotyping analyses of recipient peripheral 
blood over time. Finally, aneuploid HSCs can be transplanted into euploid recipient mice, 
thus offering a unique model for studying aneuploid cells in the context of a euploid 
environment, a setting more typical of sporadic human cancers in vivo.
ROBERTSONIAN CHROMOSOMES AS A TOOL TO GENERATE ANEUPLOID 
HSCs
Because we are particularly interested in evaluating the effects of aneuploidy on cellular 
fitness in vivo, we sought to utilize this transplantation system in particular to study trisomic 
HSCs. Although trisomy is usually embryonic lethal in mice—precluding the analysis of 
animals with constitutional aneuploidies—some trisomic mice survive to E14.5, enabling 
isolation of HSCs from the fetal liver and thus permitting analysis of trisomic HSCs in 
adoptive transfers.
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We employ a genetic system that relies on Robertsonian translocations to generate trisomic 
embryos (Figure 4; Williams et al. 2008). The breeding scheme to generate these trisomic 
animals was originally developed by Alfred Gropp and colleagues (Gropp et al. 1972). 
Gropp and colleagues discovered that feral house mice caught in Switzerland have 26 
chromosomes instead of the 40 chromosomes previously found in mice (Gropp et al. 1969; 
Hsu and Benirschke 1970). This mouse, called the “tobacco mouse” because of its dark 
brown coat color, was initially thought to be a different species because it had fewer 
chromosomes and showed reduced fertility when mated with laboratory strains. However, 
further analysis revealed that the genome of these mice had the same complement of 
chromosomes as laboratory mice but that it was comprised in part by 7 Robertsonian 
translocations (Figure 5; Gropp et al. 1972; Hsu and Benirschke 1970). A number of other 
Robertsonian translocations have since been isolated from feral mouse populations in 
Europe, Africa and Asia (Capanna and Castiglia 2004), enabling the isolation of most 
combinations of Robertsonian translocations for laboratory use.
To generate trisomic mice (Figure 4), mice homozygous for a single Robertsonian 
translocation of two chromosomes (e.g. Rb 13.16) are crossed to mice homozygous for 
another Robertsonian translocation that includes one chromosome found in the first 
Robertsonian translocation fused with another chromosome (e.g. Rb 16.17). Male mice that 
are heterozygous for these Robertsonian translocations—“compound heterozygotes”—
though genetically euploid themselves, give rise to trisomic embryos upon mating with wild 
type females when meiotic nondisjunction occurs in the male germline. The frequency of 
non-disjunction is increased in this system because more than two chromosomes will 
recombine during meiosis I, creating multivalents and hence causing mis-segregation to 
occur more often. The corresponding monosomic embryos are not observed, as they die in a 
very early stage of embryonic development (Gropp 1982).
Initial characterization of all possible trisomic mice that could be generated using the 
available Robertsonian translocations revealed that trisomy is generally embryonic lethal in 
mice, with different trisomies causing lethality at different developmental stages (Gropp 
1982). However, Gropp and coworkers did observe live birth of some trisomic animals, 
including those trisomic for chromosomes 13, 16 and 19. This phenotypic heterogeneity is 
likely due to the fact that feral mice harboring Robertsonian chromosomes were outcrossed 
to laboratory strains to isolate specific fusion chromosomes. Such mating procedures 
typically result in “hybrid vigor,” or heterosis, a condition of increased fitness due to 
heterozygosity of alleles at many loci (Birchler et al. 2006). While this system makes 
studying trisomic embryos easier because of increased fitness, it can make further genetic 
studies of the progeny of these strains difficult to interpret because of a wide range of 
genetic variability (Simpson et al. 1997). Indeed, matings of these feral strains with different 
laboratory strains led to strain-specific differences in trisomic embryo survival (Gropp et al. 
1983).
To reduce this genetic variability for research purposes, inbred syngeneic strains generated 
by breeding siblings for hundreds of generations are used (Silver 1995). Inbreeding results 
in homozygosity of all alleles in the genome but also causes decreased fitness, known as an 
inbreeding depression (Charlesworth and Charlesworth 1987). This decreased fitness is 
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thought to be due to factors such as fixation of deleterious alleles in the strain background 
and a reduced ability to respond to environmental challenges. Thus, crossing of mice with an 
established inbred strain for many filial generations reduces genetic variability of strains – 
making phenotypes easier to interpret – but also results in decreased fitness.
BACKCROSSING REDUCES TRISOMIC EMBRYO FITNESS
Our lab undertook the effort of backcrossing a number of mouse strains harboring 
Robertsonian translocations into the inbred mouse strain C57BL/6J. The generation of 
backcrossed strains was especially important for adoptive transfer experiments to prevent 
graft rejection. Conditions such as graft-versus-host disease occur during HSC 
transplantation due to histoincompatibility (Allen et al. 1999). Graft-versus-host disease 
occurs when donor-derived T cells recognize the recipient as “non-self” and attack the 
recipient cells (Shlomchik 2007), often resulting in death or a chronic autoimmune-like 
condition following transplantation. The use of inbred mouse strains eliminates such 
complications.
Histoincompatibility likely affected previous adoptive transfers with trisomic HSCs. HSCs 
derived from mouse embryos trisomic for six different chromosomes were shown to be 
capable of repopulating the bone marrow of lethally irradiated mice in adoptive transfers 
(Herbst and Winking 1991a). Several hematopoietic phenotypes were observed in the 
recipients in this study. Mice reconstituted with trisomy 16 fetal liver cells showed decreased 
survival, anemia—decreased red blood cell counts—and leukopenia—decreased white blood 
cell counts. Mice reconstituted with trisomy 19 HSCs also showed leukopenia, and mice 
reconstituted with trisomy 13 HSCs showed decreased survival. However, because this study 
utilized non-backcrossed animals, the results were likely affected by graft rejection factors 
such as delayed graft-versus-host disease (Lowenberg 1977; Gropp et al. 1983), as only 70% 
of control animals survived at 9 weeks after adoptive transfers (Herbst and Winking 1991b). 
This high incidence of lethality in even control recipient mice makes the observed 
differences in survival and peripheral blood counts between trisomic and euploid 
reconstitutions difficult to interpret. Backcrossing the Robertsonian strains into an inbred 
line both reduces lethality due to histoincompatibility and ensures the phenotypes observed 
are due to differences in the donor HSCs and not a consequence of delayed graft rejection in 
the recipients.
We initially selected three trisomic strains, trisomy 13, 16 and 19, to perform adoptive 
transfer experiments because they span a distribution of mouse chromosome sizes: 
chromosomes 13 and 16 are intermediate sized chromosomes and chromosome 19 is the 
smallest mouse autosome. Additionally, these trisomic embryos were shown to survive to 
late stages of embryogenesis in initial characterizations in mixed backgrounds (Gropp 
1982). We backcrossed mice harboring the Robertsonian chromosomes required to generate 
these trisomies for 10 generations into the C57BL/6J inbred background, leading to an 
estimated homozygosity of 99.9%. To evaluate the impact of backcrossing on trisomic 
embryo fitness, we documented the results of efforts to isolate these trisomic embryos. Our 
breeding data indicate that backcrossing these Robertsonian chromosomes has likely led to 
reduced embryonic survival for all three trisomies (Table 1).
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Timed matings were employed to harvest trisomic embryos at E13.5 or E14.5, when HSCs 
could be readily isolated from fetal livers. Compound heterozygous males were mated with 
wild type C57BL/6J females, and embryos were harvested from pregnant females 13 or 14 
days after successful mating. Trisomic embryos were initially distinguished from euploid 
embryos by gross morphological characteristics: trisomic embryos are smaller and generally 
paler than their wild type littermates and exhibit nuchal edema, a build-up of fluid on the 
spine (Gropp et al. 1983; Williams et al. 2008). However, the karyotype of embryos deemed 
trisomic was later confirmed by chromosome spreads and qPCR.
Embryos that die mid-gestation are resorbed into the maternal circulation over the course of 
a few days and can be detected in the uterine horn during this time (Flores et al. 2014). A 
previous study detected low numbers of resorbed embryos between E13.5 and E15.5 in 
matings of 3–7 month old C57BL/6J females with C57BL/6J male mice (Table 1; Holinka et 
al. 1979).
Previous characterizations of trisomy 16 in outcrosses yielded about 20% trisomic progeny 
at E14 (Miyabara et al. 1982). Trisomy 19 embryos were obtained at an even higher 
frequency (White et al. 1974a; 1974b). These studies also showed that these trisomic strains 
frequently survived until at least E16, and sometimes even survived to birth depending on 
the strain background used. As shown in Table 1, backcrossing into the C57BL/6J 
background greatly reduced the frequency at which trisomic embryos were obtained with 
our Robertsonian lines. For trisomy 13, the number of successful matings was low and 
yielded only one trisomic embryo (0.8% of all embryos isolated). Crosses to obtain trisomy 
16 and 19 embryos led to pregnancies in approximately half of attempted matings, and 
trisomic embryos represented only about 12 and 16%, respectively, of all embryos isolated 
(Table 1). This decreased yield in trisomic embryos makes the isolation of trisomic fetal 
liver cells challenging, especially given that trisomy 16 and 19 fetal livers on average yield 
about 50% and 70% fewer cells than the livers isolated from their wild type littermates, 
respectively (data not shown). These data suggest that trisomic embryos of the C57BL/6J 
background will not survive to late embryonic development as frequently as previously 
characterized trisomic embryos.
While backcrossing likely led to decreased recovery of trisomic embryos at this embryonic 
stage, there are a number of additional factors that could have also influenced this decrease 
in later term embryo survival. Variable rates of chromosome mis-segregation were observed 
in the original hybrid strains both for different Robertsonian translocations and in male and 
female mice ranging from 4 to 26% when mating two compound heterozgyotes (Gropp et al. 
1974). We have not evaluated the rate of chromosome mis-segregation in strains carrying 
Robertsonian fusion chromosomes after backcrossing; however, the presence of multiple 
resorbed embryos in most litters (Table 1) suggests that trisomic embryos are being 
produced. Additionally, we chose to use male compound heterozygotes to generate trisomic 
embryos because they can be mated multiple times. However, chromosome mis-segregation 
was reported to be lower in male than in female compound heterozygotes (Gropp et al. 
1974). Indeed, recent breedings with female compound heterozygotes harboring the 11.13 
and 13.16 Robertsonian chromosomes have yielded several trisomic embryos at E13.5 (P. 
Hsu, personal communication), suggesting that low mis-segregation rate – or likely male 
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sterility (Gropp et al. 1983) – in these compound heterozygotes may be an additional factor 
limiting embryo production.
It is important to note that we did not attempt to isolate embryos before or after E13.5 – 
E15.5. It is thus possible that more trisomic embryos could have been recovered earlier in 
development. Consistent with this idea is the observation that while only half of the 
pregnancies aimed at obtaining trisomy 16 and trisomy 19 yielded trisomic embryos when 
harvested between E13.5 and E15.5, nearly all contain resorbed embryos. Further, because 
we did not isolate embryos after E15.5, it is possible that embryos surviving to E15.5 may 
have survived longer. Thus, our data provide us with only an estimate for a range of 
embryonic survival after backcrossing. Regardless, these data demonstrate that backcrossing 
of the Robertsonian chromosomes has led to decreased embryonic fitness.
TOWARDS AN IN VIVO SYSTEM TO STUDY ANEUPLOID CELLS
Although backcrossing into an inbred line led to reduced organismal fitness of the trisomic 
embryos, we have focused on characterizing the in vivo fitness of HSCs from two of the 
trisomic mouse strains that could be successfully isolated, trisomy 19, the smallest mouse 
autosome, and trisomy 16, the closest whole-chromosomal mouse model for human DS. 
Using our backcrossed animals, we have begun flow cytometric analyses of trisomic blood 
lineages in vivo to quantitatively assess differences in reconstitution in recipient mice over 
an extended period of time. We are also utilizing improved HSC characterization methods 
(Kiel et al. 2005; Kim et al. 2006; Yilmaz et al. 2006) to better understand the source of 
potential hematopoietic defects.
We complement our studies of constitutional trisomic HSCs with the analysis of HSCs 
harboring random aneuploidies that are generated by mouse models with increased rates of 
chromosome mis-segregation. The mouse model we first utilized to characterize HSCs with 
CIN harbors a hypomorphic allele of the spindle assembly checkpoint protein BubR1 
(BUB1BH/H; Baker et al. 2004). The spindle assembly checkpoint ensures proper 
chromosome segregation. Thus, when BubR1 function is compromised by this loss-of-
function allele, chromosomes mis-segregate more frequently, resulting in a randomly 
aneuploid cell population containing cells with one or more whole chromosomal 
aneuploidies mixed with euploid cells. The BubR1 hypomorphic allele is better tolerated 
than constitutional trisomy, as these mice survive to adulthood with a mean life expectancy 
of 6 months; however these mice have a progeroid phenotype and become progressively 
more aneuploid with age as evaluated by metaphase spreads of stimulated splenocytes 
(Baker et al. 2004). The use of BubR1H/H cells enables us to differentiate between 
chromosome-specific effects and general aneuploidy effects. Furthermore, because this 
mouse model survives to adulthood, both fetal liver and bone marrow HSCs can be 
evaluated from BubR1H/H mice. Finally, having a mouse model of CIN enables us to 
determine whether observed phenotypes are graded depending on the severity of the 
aneuploidy present, as has been seen previously in yeast and murine tissue culture (Torres et 
al. 2007; Williams et al. 2008).
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HEMATOPOIESIS IN DS AND MOUSE MODELS OF DS
In addition to providing insights into the effects of aneuploidy on cellular fitness and 
tumorigenesis, the trisomy 16 mouse model is also relevant to DS, as DS individuals exhibit 
a number of hematopoietic phenotypes, including an increased risk of leukemia in the first 
few years of life (Satge et al. 1998). Most DS individuals who develop cancer show 
perturbed hematopoiesis before the onset of the disease. Neutrophilia, increased neutrophil 
counts, thrombocytopenia, decreased platelet counts, and polycythemia or increased 
hemoglobin concentration in the peripheral blood – manifest in 80, 66 and 34% of DS 
newborns, respectively (Choi 2008; Henry et al. 2007). These aberrations can also be 
detected in human trisomy 21 fetal livers. Trisomy 21 fetal livers harbor higher numbers of 
HSCs and megakaryocyte-erythroid progenitors and decreased numbers of B cell 
progenitors (Roy et al. 2012; Chou et al. 2008). Similar perturbations in the myeloid lineage 
were observed in HSCs derived from trisomy 21 induced pluripotent stem cells (Chou et al. 
2012; Maclean et al. 2012). Furthermore, about 10% of DS infants develop transient 
myeloproliferative disorder (TMD), a condition caused by increased proliferation in the 
myeloid lineage that is usually apparent within the first few weeks of life and generally 
spontaneously resolves within 3 months (Choi 2008). This alteration in the myeloid lineage 
can be attributed to both trisomy 21 and mutations in the transcription factor GATA1 
(Mundschau et al. 2003). In some cases, TMD will progress to acute myeloid leukemia 
(Alford et al. 2011). Additionally, while not present at birth (Henry et al. 2007), 
macrocytosis – increased cell volume – of red blood cells has been observed in children with 
DS analyzed between the ages of 2 and 15 (David et al. 1996).
Perturbations in blood lineages are also observed in mouse models of DS. The Ts65Dn 
mouse model – which harbors an extra copy of about two-thirds of the mouse genes 
orthologous to human chromosome 21 – shows sustained macrocytic anemia—increased red 
blood cell volume accompanied by decreased red blood cell counts and blood hemoglobin 
concentration—and increased numbers of megakaryocytes and common myeloid progenitors 
in the bone marrow (Kirsammer et al. 2008). The Ts1Cje mouse model – which contains 
about two-thirds of the genes amplified in the Ts65Dn mouse model – also exhibits 
macrocytic anemia throughout life; however, no differences in the myeloid lineage were 
observed, even after a loss-of-function allele of GATA1 was introduced into the line 
(Carmichael et al. 2009). The Tc1 mouse model – which harbors an exogenous copy of 80% 
of human chromosome 21– also showed macrocytic anemia throughout life (Alford et al. 
2010). Introduction of a mutant, truncated form of GATA1 induced increased 
megakaryopoiesis in this model, but was not sufficient to induce leukemia (Alford et al. 
2010).
In summary, there is evidence for perturbations of the hematopoietic lineages in both 
humans with DS and mouse models of DS. While the phenotypes observed are variable, 
there are some features frequently shared by humans and mice. For example, macrocytosis is 
observed both in some individuals with DS and in all DS mouse models studied. Notably, 
increased cell volume is also a feature of aneuploid cells in general (Torres et al. 2007; 
Williams et al. 2008). Further study of the effect of aneuploidy on HSCs using mouse 
models of trisomy and CIN will permit evaluation of these phenotypes in the context of 
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different chromosomal amplifications. This evaluation will determine whether these 
phenotypes are specific to the particular amplification of the set of genes present on human 
chromosome 21 or if some of these phenotypes can be attributed to a general cellular 
response to aneuploidy in the blood.
ADOPTIVE TRANSFER AS A TOOL TO STUDY ANEUPLOID 
HEMATOPOIETIC MALIGNANCIES
It is still not well understood why cancer cells are aneuploid. However, adaptation of the 
system described here could provide a unique way to assess the effects of a range of 
aneuploid cells on tumorigenesis in vivo. HSCs can be transduced in vitro and then 
transplanted into irradiated recipients. If transduced with oncogenes, this system can be used 
to induce leukemias and lymphomas (Schmitt et al. 2000; 2002; Hemann et al. 2005). 
Additionally, leukemias and lymphomas are often transplantable and amenable to 
manipulation in culture, making this a potentially powerful system to assess the role of 
cellular aneuploidy in tumorigenesis in the future without requiring repeated isolations of 
trisomic fetal liver cells. This system will greatly expand the range of our in vivo analysis 
model, allowing us to assess the combinations of many aneuploidies and oncogenes on the 
kinetics of transformation in leukemia and lymphoma in mice and enabling us to test the 
effect of aneuploidy-targeting drugs (Tang et al. 2011) in aneuploid blood cancers.
CONCLUSIONS
Aneuploidy is a generally detrimental cellular state that exhibits a complicated relationship 
with cancer. We are working towards establishing a cellular system to better understand this 
relationship in vivo in mice by characterizing the fitness and differentiation potential of 
HSCs with trisomy or harboring mutations that cause CIN. Establishment and 
characterization of this system also permits future evaluation of the role of aneuploidy in 
tumorigenesis through the activation of oncogenes or inactivation of tumor suppressor genes 
before transplantation. We hope that our findings and future work using this system will help 
clarify the effects of aneuploidy in DS and provide insight into the precise role of 
aneuploidy in cancer.
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FIGURE 1. Hematopoiesis
Hematopoiesis is initiated by a hematopoietic stem cell that can either divide to self-renew 
or to produce a cell that will become a common lymphoid progenitor or a common myeloid 
progenitor. These common progenitors further divide to self-renew or to differentiate into 
several types of committed progenitor cells that will ultimately give rise to all the 
differentiated cell types in the blood.
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FIGURE 2. Ontogeny of the hematopoietic stem cell in mice
Primitive HSCs arise around E7.5 in yolk sac blood islands (highlighted in red). These cells 
do not contribute to the adult HSC pool. Definitive HSCs are largely formed around E10.5 in 
the aorta-gonad-mesonephros (AGM) region (highlighted in red). These cells migrate to the 
fetal liver (highlighted in red), where they rapidly proliferate for several days before 
migrating to the bone marrow (highlighted in red) during late embryonic development. 
HSCs largely remain in the bone marrow throughout adulthood.
Pfau and Amon Page 15
Cold Spring Harb Symp Quant Biol. Author manuscript; available in PMC 2016 October 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 3. Adoptive transfer of fetal liver or bone marrow cells
Donor cells containing HSCs are isolated from either the fetal liver or bone marrow of mice 
expressing the CD45.2 cell surface antigen. These cells are transferred by injection into 
irradiated recipient mice that express the CD45.1 cell surface antigen. Donor cells can later 
be detected in the peripheral blood of the recipient by flow cytometry using antibodies that 
distinguish between CD45.1 and CD45.2 expressing cells.
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FIGURE 4. Breeding schematic for generating trisomic mice
Mice homozygous for a Robertsonian translocation of two chromosomes are crossed to mice 
homozygous for a different Robertsonian translocation. Importantly, one chromosome is 
shared in each of the two Robertsonian translocations. The resulting mice, which are 
heterozygous for both of these Robertsonian translocations, are called “compound 
heterozygotes.” When meiotic nondisjunction occurs in the germline of compound 
heterozygotes and both Robertsonian chromosomes are segregated into the same gamete, a 
trisomic embryo is produced upon fertilization. Male compound heterozygotes were utilized 
in our studies to permit repeated matings. Potential male gametes are shown in blue, and 
potential female gametes are shown in pink. Monosomic embryos are not observed, as they 
die in a very early stage of embryonic development.
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FIGURE 5. Tobacco mouse karyogram
Chromosome spreads of (A) male and (B) female mice reveals the karyotype of the tobacco 
mouse. This feral mouse contains 7 Robertsonian fusion chromosomes and 19 acrocentric 
chromosomes, for a total of 26 chromosomes. Reprinted with permission from (Hsu and 
Benirschke 1970).
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